The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: STSA-1005 injectionDrug: Placebo
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Staidson Biopharma Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05085197
- Locations
- 🇺🇸
AltaSciences Clinical Kansas, Inc, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath